Press release
Obesity Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Stay ahead with the latest insights! Download DelveInsight's comprehensive Obesity Pipeline Report to explore emerging therapies, key Obesity Companies, and future Obesity treatment landscapes @ Obesity Pipeline Outlook Report [https://www.delveinsight.com/sample-request/obesity-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Obesity Pipeline Report
* In April 2025, Carmot Therapeutics Inc. announced a phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Weekly CT-388 Administered Subcutaneously for 48 Weeks to Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus.
* In April 2025, BrightGene Bio-Medical Technology Co., Ltd. conducted a phase II, Randomized Open-label, Multicenter Study to Evaluate the Efficacy and Safety of BGM0504 Compared to Tirzepatide in Adults Who Have Obesity.
* In April 2025, Arrowhead Pharmaceuticals organized a phase 1/2a double-blind dose-escalating study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple doses of ARO-INHBE in adult participants with obesity (Part 1), and the safety, tolerability and PD of multiple doses of ARO-INHBE in adult participants with obesity with and without type 2 diabetes mellitus receiving tirzepatide (Part 2).
* In April 2025, Novo Nordisk A/S announced a study looks at how well semaglutide helps people lose weight. This study will look at the change in the participants' body weight from the start to the end of the study. The study compares the weight loss in people who get semaglutide to the weight loss in people who get placebo. Placebo is a "dummy" medicine that looks like the study medicine, but has no effect on the body.
* In April 2025, Boehringer Ingelheim announced a study is to find out whether a medicine called survodutide (BI 456906) helps people living with overweight or obesity to lose weight. Participants are divided into 3 groups by chance, like drawing names from a hat. 2 groups get different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Every participant has a 2 in 3 chance of getting survodutide.
* DelveInsight's Obesity pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Obesity treatment.
* The leading Obesity Companies such as Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus , and others.
* Promising Obesity Therapies such as APHD-012, Bimagrumab, Semaglutide, CT-868, GLY-200, Bremelanotide , and others.
Discover how the Obesity treatment paradigm is evolving. Access DelveInsight's in-depth Obesity Pipeline Analysis for a closer look at promising breakthroughs @ Obesity Clinical Trials and Studies [https://www.delveinsight.com/sample-request/obesity-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Obesity Emerging Drugs
* Survodutide: Zealand Pharma
Survodutide (BI 456906) is a long-acting glucagon/GLP-1 receptor dual agonist for once-weekly subcutaneous administration that activates two key gut hormone receptors simultaneously and may offer better efficacy than current single-hormone receptor agonist treatments. Survodutide is targeting the treatment of obesity and nonalcoholic steatohepatitis (NASH). Boehringer Ingelheim is advancing survodutide into three global Phase III trials in people living with overweight or obesity.
* Ecnoglutide: Sciwind Biosciences
Glucagon-like peptide-1 (GLP-1) analogs are effective therapies in managing type 2 diabetes, obesity, and have demonstrated clinical potential as a treatment for NASH. Ecnoglutide (XW003) is a novel, cAMP signaling biased, long-acting GLP-1 analogue optimized for improved biological activity, cost-effective manufacturing, and once weekly dosing. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Obesity.
* CT-868: Carmot Therapeutics
CT-868 is a dual GLP-1 and GIP receptor modulator with a unique pharmacological profile optimized for improved tolerability at the GLP-1 receptor. The combined action of GLP-1 and GIP results in greater body weight loss and glucose control. CT-868 is dosed once daily to maximize efficacy and tolerability. CT-868 dual agonist candidate was discovered using the chemotype evolution technology as a peptide-small molecule hybrid compound, able to mimic the native GLP-1 hormone. In the Phase I trial, CT-868 demonstrated compelling pharmacodynamic activity across several clinical measures in overweight and obese healthy individuals a safe and generally well-tolerated profile. Carmot Therapeutics is now expanding the observations in overweight and obese patients with type 2 diabetes to demonstrate CT-868's effects on glycemic control, weight loss, and tolerability. Currently, the drug is in the Phase II stage of development to treat obesity.
* DD01: D&D Pharmatech
DD01 is a proprietary, imbalanced dual agonist of GLP-1 and glucagon receptors with a half-life of 11 days in non-human primates. DD01 is being developed as a potential disease-modifying agent for obesity and liver fatty disease. Treatment with DD01 caused weight loss, reduced liver fat, and improved glucose tolerance in preclinical obesity, diabetes, and fatty liver models. In preclinical models of diabetes and nonalcoholic fatty liver disease (NAFLD), DD01 could reduce weight and blood sugar and improve insulin sensitivity and lipid and fat metabolism, which could ameliorate NASH. DD01 demonstrated greater efficacy in preclinical models than semaglutide, an approved GLP-1R receptor agonist; from a mechanical perspective, the effect of DD01 persisted after cessation of treatment. It is currently being evaluated in Phase I clinical trial to investigate the safety, tolerability, PK, and PD of DD01 administered by subcutaneous (SC) injection in overweight/obese subjects with type 2 diabetes mellitus and nonalcoholic fatty liver disease (NAFLD).
The Obesity pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Obesity with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Obesity Treatment.
* Obesity Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Obesity Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Obesity market.
Get a detailed analysis of the latest innovations in the Obesity pipeline. Explore DelveInsight's expert-driven report today! @ Obesity Unmet Needs [https://www.delveinsight.com/sample-request/obesity-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Obesity Companies
Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others.
Obesity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Obesity Products have been categorized under various ROAs such as
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical
Obesity Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Download DelveInsight's latest report to gain strategic insights into upcoming Obesity Therapies and key Obesity Developments @ Obesity Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/obesity-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Obesity Pipeline Report
* Coverage- Global
* Obesity Companies- Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus , and others.
* Obesity Therapies- APHD-012, Bimagrumab, Semaglutide, CT-868, GLY-200, Bremelanotide , and others.
* Obesity Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Obesity Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Obesity drug development? Find out in DelveInsight's exclusive Obesity Pipeline Report-access it now! @ Obesity Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/obesity-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Obesity Overview
* Obesity Pipeline Therapeutics
* Obesity Therapeutic Assessment
* Late Stage Products (Phase III)
* Survodutide: Zealand Pharma
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* CT-868: Carmot Therapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* DD01: D&D Pharmatech
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Obesity Products
* Obesity Key Companies
* Obesity Key Products
* Obesity Unmet Needs
* Obesity Market Drivers
* Obesity Market Barriers
* Obesity Future Perspectives and Conclusion
* Obesity Analyst Views
* Obesity Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=obesity-clinical-trials-and-studies-2025-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Obesity Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies here
News-ID: 3959424 • Views: …
More Releases from ABNewswire
Non-Small Cell Lung Cancer Market Positioned for Accelerated Development Through …
The Key Non-Small Cell Lung Cancer Companies in the market include - AbbVie, AstraZeneca and Daiichi Sankyo, Shanghai Henlius Biotech, Moderna Therapeutics/ Merck, BeyondSpring, Cullinan Oncology/ Taiho Pharma, Genentech/Roche, Betta Pharma/ Xcovery, Pfizer, Takeda Pharmaceuticals, AstraZeneca, Janssen, Boehringer Ingelheim, Pfizer, Merck, Bristol-Myers Squibb/Ono Pharmaceutical, Genentech/ Hoffmann-La Roche, AstraZeneca, Amgen, Blueprint Medicines/Rigel Pharmaceuticals, and others.
The Non-Small Cell Lung Cancer (NSCLC) market was valued at approximately USD 32 billion in 2025 and…
Vietnamese University Students Publish 'Vietnam Hangeul Newspaper' ... K-Wave No …
Image: https://www.abnewswire.com/upload/2025/10/fe9c4c1c8de543dfef7abbb9c8e22d9d.jpg
Vietnamese youth are attracting attention from Korea and around the world by producing a newspaper written entirely in Hangeul, the Korean alphabet. First launched online in January, the "Vietnam Hangeul Newspaper" is a regular publication created by students from six Vietnamese universities. While it is common for non-English-speaking countries to publish newspapers in English, this marks the world's first instance of local students voluntarily producing a newspaper in Hangeul.
Currently,…
From Culture Kings to Creator Army: Simon Beard Announces New AI Content Venture
Simon Beard, co-founder of Culture Kings, launches Creator Army-an AI-assisted content bootcamp and on-demand marketplace for creators.
Gold Coast, Australia - October 7, 2025 - Serial entrepreneur Simon Beard, best known as the founder of global streetwear retailer Culture Kings, this week announced the forthcoming launch of his latest venture, Creator Army-an AI-assisted content creation platform and on-demand marketplace built to empower the next generation of creators and help businesses access…
Experts Pick SendTurtle in Roundup of Best File Transfer Tools for Security-Cons …
Recognition highlights SendTurtle's unique blend of privacy-first design, AI analytics, and seamless user experience.
Arlington, VA - SendTurtle, the SaaS platform redefining how startups, consultants, and business leaders share documents, today announced that it has been recognized by industry experts in a recent roundup of the best file transfer tools for security-conscious teams. The acknowledgment underscores SendTurtle's rapid rise as the trusted platform for secure, frictionless file sharing with built-in intelligence.
Unlike…
More Releases for Obesity
Anti-Obesity Drugs Market Grows Rapidly, Driven by Obesity Rates and Therapeutic …
Anti-Obesity Drugs Market valued at USD 5.9 Bn in 2024, growing at 16.5% CAGR to reach USD 20.02 Bn by 2032. Driven by GLP-1 therapies and rising obesity rates.
Anti Obesity Drugs Market Overview:
The anti-obesity drugs market is undergoing significant transformation as awareness about obesity-related health risks rises globally. With growing concern over lifestyle-related disorders, there is an increasing emphasis on medical intervention as a complement to traditional weight management strategies.…
Fuzzle joins The Obesity Society & The Obesity Action Coalition; Promotes Habit- …
Building healthy, sustainable habits for long-term weight management success.
Tampa, FL - March 18, 2025 - Fuzzle, an emerging leader in the wellness landscape, is pleased to announce that it's now a Member of The Obesity Society, as well as the Obesity Action Coalition, marking a new milestone in the company's mission to transform how individuals approach weight loss.
Image: https://www.globalnewslines.com/uploads/2025/03/77da787ae98a633847c70fc22e2943c7.jpg
Fuzzle supports individuals in their wellness journey through non-invasive, drug-free strategies. With…
Pediatric Obesity Management Market - Healthy Habits for Life: Advancing Pediatr …
Newark, New Castle, USA: The "Pediatric Obesity Management Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Pediatric Obesity Management Market: https://www.growthplusreports.com/report/pediatric-obesity-management-market/8930
This latest report researches the industry structure,…
Anti-Obesity Drugs Market - From Obesity to Vitality: Leading the Way in Effecti …
Newark, New Castle, USA - new report, titled Anti-Obesity Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Anti-Obesity Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Anti-Obesity Drugs market. The report offers an overview of the market, which…
Increasing Prevalence of Obesity Driving Obesity/Bariatric Surgery Devices Marke …
The global obesity/bariatric surgery devices market revenue stood at $1.4 billion in 2016, and it is expected to rise to $2.8 billion by 2023. Furthermore, the market will progress at a CAGR of 9.9% from 2017 to 2023 (forecast period), as per the estimates of the market research company, P&S Intelligence. The major growth drivers of the market are the rising incidence of obesity, owing to unhealthy diets and lifestyle…
Fast Food and Obesity
Most of the fast food in the market contains a large quantity of sugar, #carbs and fats with a lesser quantity of vitamins and minerals. The unhealthy food ingredients in the fast food are further increased with increased portion size. The person will still consume the whole meal regardless of being completely full. People cannot stop ravishing on fast food because it is available for low cost and in close…
